Quarterly report [Sections 13 or 15(d)]

Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)

v3.25.2
Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)
 1 Months Ended
Aug. 31, 2024
GBP (£)
Jun. 30, 2024
GBP (£)
Dec. 31, 2023
GBP (£)
Sep. 30, 2023
GBP (£)
Jun. 30, 2023
GBP (£)
Jun. 30, 2025
USD ($)
Apr. 06, 2023
USD ($)
Apr. 06, 2023
GBP (£)
Revenue                
Aggregate amount of the transaction price that is allocated to performance obligations           $ 121,309,000    
GSK Termination and Transfer Agreement                
Revenue                
Upfront payment received | £         £ 7,500,000      
Milestone payment | £ £ 1,500,000 £ 6,000,000 £ 12,000,000 £ 3,000,000        
Amount of transaction price of the agreement at inception             $ 37,335,000  
Upfront and milestone payment receivable | £               £ 30,000,000
Aggregate amount of the transaction price that is allocated to performance obligations           23,374,000    
IGNYTE                
Revenue                
Aggregate amount of the transaction price that is allocated to performance obligations           7,542,000    
LTFU                
Revenue                
Aggregate amount of the transaction price that is allocated to performance obligations           $ 15,832,000